Owen A. O’Connor
Vesuvius (United Kingdom)(GB)Virginia Cancer Institute(US)University of Virginia Cancer CenterUniversity of Virginia(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Histone Deacetylase Inhibitors Research, T-cell and Retrovirus Studies, Ubiquitin and proteasome pathways
Most-Cited Works
- → Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer(2005)903 cited
- → Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity(2010)845 cited
- → Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies(2002)761 cited
- → Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial(2018)710 cited
- → Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma(2006)706 cited
- → Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model